search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


BeSt Treatment Strategies. A randomized clinical trial to test the effectiveness of different treatment-strategies in patients with early rheumatoid arthritis. Long term follow-up.


- candidate number1458
- NTR NumberNTR265
- ISRCTNFollow-up of ISRCTN32675862
- Date ISRCTN created
- date ISRCTN requested18-okt-2005
- Date Registered NTR8-sep-2005
- Secondary IDsN/A 
- Public TitleBeSt Treatment Strategies. A randomized clinical trial to test the effectiveness of different treatment-strategies in patients with early rheumatoid arthritis. Long term follow-up.
- Scientific TitleBeSt Treatment Strategies. A randomized clinical trial to test the effectiveness of different treatment-strategies in patients with early rheumatoid arthritis. Long term follow-up.
- ACRONYMBeSt
- hypothesis1. Earlier identified differences in functional ability and radiological damage progression are maintained in the next ten years; 2. Early suppression of disease activity results in long term improvement in functional ability and suppression of joint damage progression; 3. Clinical remission can be maintained after discontinuation of all antirheumatic drugs in identifiable patients; 4. There is a clinically and statistically significant difference in extra-articular manifestations and side effects of medication between patients in the various treatment groups.
- Healt Condition(s) or Problem(s) studiedRheumatoid arthritis
- Inclusion criteriaAll patients who completed participation in the first 2 years of BeSt.
- Exclusion criteriaN/A
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-aug-2004
- planned closingdate1-aug-2012
- Target number of participants500
- InterventionsContinued treatment with established antirheumatic drugs according to accepted treatment strategies, with threemonthly treatment adjustments dictated by the height of the DAS: if DAS>2.4, than medication will be increased or changed, if, for at least 6 months DAS <2.4, medication will be tapered, if, for at least 6 months DAS <1.6, medication will be stopped.
- Primary outcome1. Functional ability as measured by HAQ;
2. Radiological damage as measured by Sharp/van der Heijde score of hands and feet;
3. Side effects and extra-articular manifestations (as reported and as monitored through laboratory assessments, X-rays, DEXAs).
- Secondary outcome1. Quality of life;
2. Utilities;
3. Work participation;
4. Costs.
- Timepoints
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESMD. C.F. Allaart
- CONTACT for SCIENTIFIC QUERIESMD. C.F. Allaart
- Sponsor/Initiator Leiden University Medical Center (LUMC)
- Funding
(Source(s) of Monetary or Material Support)
Schering-Plough, Dutch Health Care Insurance Board (CVZ, independent governement organisation), Centocor BV Leiden
- PublicationsN/A
- Brief summaryN/A
- Main changes (audit trail)
- RECORD8-sep-2005 - 8-jan-2007


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl